TABLE 2.
Baseline Characteristics of HOPD and Alternative SOC Infusions Before and After Matching
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Baseline characteristic | HOPD (n = 29,739) | Alternative SOC (n = 272,835) | SMD | HOPD (n = 26,380) | Alternative SOC (n = 26,380) | SMD |
| Patient baseline characteristics | ||||||
| Age on infusion date (in years) | 48.75 | 50.87 | −0.13 | 48.38 | 48.96 | −0.03 |
| Sex | ||||||
| Female | 69% | 68% | 0.02 | 68% | 70% | −0.03 |
| Male | 31% | 32% | −0.02 | 32% | 30% | 0.03 |
| Race and ethnicity | ||||||
| Asian | 2% | 3% | −0.08 | 2% | 3% | −0.03 |
| Black | 9% | 6% | 0.12 | 10% | 8% | 0.06 |
| White | 76% | 73% | 0.05 | 76% | 78% | −0.04 |
| Hispanic | 5% | 6% | −0.04 | 5% | 5% | 0.03 |
| Other/unknown | 8% | 12% | − | 7% | 7% | − |
| Census regiona | ||||||
| Northeast | 29% | 14% | − | 29% | 29% | − |
| Midwest | 25% | 21% | − | 27% | 27% | − |
| South | 32% | 40% | − | 29% | 29% | − |
| West | 14% | 25% | − | 15% | 15% | − |
| Rural | 14% | 12% | 0.07 | 14% | 13% | 0.04 |
| SES index | 2.95 | 3.01 | −0.06 | 2.96 | 2.97 | −0.01 |
| Treated chronic condition | ||||||
| Rheumatoid arthritis | 12% | 26% | −0.43 | 13% | 13% | 0.00 |
| Psoriatic arthritis | 2% | 5% | −0.21 | 2% | 2% | 0.00 |
| Multiple sclerosis | 26% | 9% | 0.39 | 22% | 22% | 0.00 |
| Crohn disease | 23% | 24% | −0.03 | 25% | 25% | 0.00 |
| Plaque psoriasis | 0% | 1% | −0.07 | 0% | 0% | 0.00 |
| Osteoporosis | 21% | 17% | 0.09 | 21% | 21% | 0.00 |
| Ulcerative colitis | 16% | 18% | −0.07 | 17% | 17% | 0.00 |
| Health status | ||||||
| ECI = 0 | 24% | 26% | −0.03 | 26% | 24% | 0.04 |
| ECI = 1 | 28% | 27% | 0.04 | 28% | 31% | −0.05 |
| ECI = 2 | 19% | 18% | 0.03 | 19% | 18% | 0.00 |
| ECI ≥ 3 | 29% | 30% | −0.03 | 27% | 27% | 0.01 |
| Lymph | 1% | 1% | 0.06 | 1% | 1% | 0.00 |
| Metastatic | 2% | 1% | 0.07 | 1% | 1% | 0.00 |
| Infusion baseline characteristics | ||||||
| Quarter of year | ||||||
| Infusion Q1 | 23% | 23% | 0.00 | 24% | 24% | 0.00 |
| Infusion Q2 | 25% | 24% | 0.01 | 25% | 25% | 0.00 |
| Infusion Q3 | 26% | 26% | 0.00 | 26% | 25% | 0.01 |
| Infusion Q4 | 26% | 26% | −0.01 | 26% | 26% | −0.01 |
| Utilization 6 months preinfusion | ||||||
| Inpatient visit | 0.10 | 0.07 | 0.06 | 0.10 | 0.07 | 0.05 |
| Outpatient visit | 11.31 | 11.33 | 0.00 | 11.07 | 11.21 | −0.01 |
| OV visit | 5.42 | 5.45 | −0.01 | 5.30 | 5.31 | 0.00 |
| ED visit | 0.17 | 0.15 | 0.04 | 0.17 | 0.14 | 0.05 |
| Other infusion agent | 61% | 52% | 0.18 | 63% | 55% | 0.15 |
| Infusion sequence number | ||||||
| Infusion number = 1 | 32% | 26% | 0.14 | 33% | 33% | 0.00 |
| Infusion number = 2 | 16% | 14% | 0.05 | 16% | 16% | 0.00 |
| Infusion number ≥ 3 | 52% | 60% | −0.17 | 52% | 52% | 0.00 |
| Infusion agent | ||||||
| J0129 | 4% | 8% | −0.24 | 4% | 4% | 0.00 |
| J0202 | 0% | 0% | 0.03 | 0% | 0% | 0.00 |
| J0717 | 1% | 4% | −0.39 | 1% | 1% | 0.00 |
| J0897 | 12% | 12% | 0.00 | 13% | 13% | 0.00 |
| J1602 | 1% | 6% | −0.41 | 1% | 1% | 0.00 |
| J1628 | 0% | 0% | −0.02 | 0% | 0% | 0.00 |
| J1745 | 21% | 26% | −0.13 | 23% | 23% | 0.00 |
| J2323 | 15% | 6% | 0.25 | 12% | 12% | 0.00 |
| J2327 | 1% | 1% | 0.05 | 1% | 1% | 0.00 |
| J2350 | 11% | 4% | 0.23 | 10% | 10% | 0.00 |
| J3111 | 2% | 3% | −0.04 | 3% | 3% | 0.00 |
| J3245 | 0% | 0% | −0.10 | 0% | 0% | 0.00 |
| J3262 | 1% | 3% | −0.17 | 2% | 2% | 0.00 |
| J3358 | 1% | 1% | 0.04 | 1% | 1% | 0.00 |
| J3380 | 14% | 18% | −0.12 | 16% | 16% | 0.00 |
| J3489 | 7% | 2% | 0.17 | 6% | 6% | 0.00 |
| J9312 | 2% | 2% | −0.01 | 2% | 2% | 0.00 |
| Q5103 | 4% | 3% | 0.09 | 4% | 4% | 0.00 |
| Q5104 | 1% | 1% | 0.05 | 1% | 1% | 0.00 |
| Q5115 | 0% | 0% | 0.03 | 0% | 0% | 0.00 |
| Q5119 | 1% | 0% | 0.07 | 0% | 0% | 0.00 |
| Q5121 | 1% | 1% | 0.01 | 0% | 0% | 0.00 |
| Q5123 | 0% | 0% | 0.02 | 0% | 0% | 0.00 |
a
Infusions were exact-matched on state of residence.
ECI = Elixhauser comorbidity index; ED = emergency department; HOPD = hospital outpatient department; OV = office visit; SOC = site of care; SES = socioeconomic status; SMD = standardized mean difference.